Page 2 - Authorization Application News Today

SKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced... | May 10, 2023

/PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered in Italy, today announced that it has partnered with Avanzanite Bioscience...

SIFI Announces License Agreement With Avanzanite Bioscience for Akantior® - read this article along with other careers information, tips and advice on BioSpace

Operator: Ladies and gentlemen, greetings and welcome to the Marinus Pharmaceuticals Third Quarter 2022 Financial Results and Business Update Call.

Ebvallo™ is the first authorised allogeneic T-cell immunotherapy and has been approved for EU patients with relapsed or refractory EBV+ PTLD.

19.12.2022 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced that the European Commission (EC) has granted marketing authorization for Ebvallo (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two ... Seite 1

Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organization in key strategic therapeutic areas: immunology and oncologyJyseleca 2022

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

Investegate announcements from Galapagos NV, Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results

EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European Commission